-
Biohaven Rallies On Preliminary Nurtec Revenue Numbers: What Investors Need To Know
Wednesday, July 7, 2021 - 3:02pm | 275Biohaven Pharmaceutical Ltd. (NYSE: BHVN) released preliminary second-quarter revenue data for its drug Nurtec ODT on Wednesday. What Happened: Nurtec achieved preliminary net product revenue of approximately $93 million in the second quarter, according to the company. Since its launch in March...